Suchergebnisse - "Venkatakrishnan, Karthik"

PubPharm (24)

1

Clinical Pharmacology of Brigatinib : A Next-Generation Anaplastic Lymphoma Kinase Inhibitor

enthalten in: Clinical pharmacokinetics | 2023

von Gupta, N. | Hanley, M. | Griffin, R. | +3

2

Response-Based Dosing for Ponatinib : Model-Based Analyses of the Dose-Ranging OPTIC Study

enthalten in: Clinical pharmacology and therapeutics | 2023

von Hanley, M. | Diderichsen, P. | Rich, B. | +5

3

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

enthalten in: Investigational new drugs | 2023

von Hanley, M. | Kerstein, D. | Tugnait, M. | +4

4

Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial : support for dosage recommendations

enthalten in: Cancer chemotherapy and pharmacology | 2022

von Xiong, W. | Hietala, S. | Nyberg, J. | +8

5

Population pharmacokinetic and exposure-response analyses from ALTA-1L : Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC

enthalten in: Clinical and translational science | 2022

von Gupta, N. | Reckamp, K. | Camidge, D. | +8

6

Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model-Informed Dose Selection for Pediatric Development

enthalten in: Journal of clinical pharmacology | 2022

von Hanley, M. | Diderichsen, P. | Narasimhan, N. | +3

7

Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies

enthalten in: Journal of clinical pharmacology | 2022

von Zhou, X. | Mould, D. | Yuan, Y. | +4

8

Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers

enthalten in: Clinical pharmacology in drug development | 2021

von Zhang, S. | Jin, S. | Griffin, C. | +4

9

Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers : Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products

enthalten in: Clinical pharmacology in drug development | 2021

von Zhang, S. | Jin, S. | Griffin, C. | +6

10

Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer : Exposure-Response Analyses of Pivotal ALTA Study

enthalten in: CPT: pharmacometrics & systems pharmacology | 2020

von Gupta, N. | Wang, X. | Offman, E. | +6

ErratumIn: CPT Pharmacometrics Syst Pharmacol. 2021 Sep;10(9):1119-1122. - PMID 34414680